ARWR vs. ELA

Last updated Aug 1, 2026

ARWR (Arrowhead Pharmaceuticals, Inc.) and ELA (Envela Corporation) are both stocks. ARWR operates in Biotechnology (Healthcare), while ELA operates in Luxury Goods (Consumer Cyclical). Over the past 10 years, ARWR returned 30.88%/yr vs 38.58%/yr for ELA. Their 0.06 correlation means their historical movements had little consistent relationship.

Performance

ARWR vs. ELA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arrowhead Pharmaceuticals, Inc. (ARWR) and Envela Corporation (ELA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ARWR achieves a 27.50% return, which is significantly lower than ELA's 62.03% return. Over the past 10 years, ARWR has underperformed ELA with an annualized return of 30.88%, while ELA has yielded a comparatively higher 38.58% annualized return.

ARWR

• 1D: -3.06%
• 1M: 0.79%
• 6M: 22.10%
• YTD: 27.50%
• 1Y: 431.39%
• 3Y*: 35.96%
• 5Y*: 4.09%
• 10Y*: 30.88%
• ALL TIME*: -0.69%

ELA

• 1D: 0.00%
• 1M: -15.18%
• 6M: 58.94%
• YTD: 62.03%
• 1Y: 294.90%
• 3Y*: 42.01%
• 5Y*: 37.44%
• 10Y*: 38.58%
• ALL TIME*: 5.79%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
ARWR Arrowhead Pharmaceuticals, Inc.	$205.45M	$188.79M	$175.31M
ELA Envela Corporation	$2.70M	$2.90M	$3.20M

ARWR vs. ELA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ARWR Arrowhead Pharmaceuticals, Inc.	27.50%	253.14%	-38.56%	-24.56%	-38.82%	-13.59%	20.97%	410.71%	237.50%	137.42%
ELA Envela Corporation	62.03%	86.35%	47.74%	-7.60%	29.24%	-21.73%	285.19%	193.54%	-50.55%	-25.00%

Correlation

The correlation between ARWR and ELA is 0.10, which is low. Their historical price movements had little consistent relationship.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.10
Correlation (3Y) Balances recent behavior with more history.	0.19
Correlation (5Y) Shows whether the relationship held over a longer period.	0.19
Correlation (10Y) Provides a long-term view across more market conditions.	0.12
Correlation (All Time) Calculated using the full available price history since Jan 6, 1997	0.06

The correlation between ARWR and ELA shifts across timeframes, from 0.06 (all time) to 0.19 (3 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap ARWR : $11.92B ELA : $562.89M
EPS ARWR : -$2.16 ELA : $0.81
PS Ratio ARWR : 19.00 ELA : 1.93
PB Ratio ARWR : 20.13 ELA : 7.42
Total Revenue (TTM) ARWR : $622.01M ELA : $291.15M
Gross Profit (TTM) ARWR : $529.27M ELA : $62.58M
EBITDA (TTM) ARWR : -$168.38M ELA : $22.99M

Return for Risk

ARWR vs. ELA — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

ARWR

ARWR Risk / Return Rank: 99
ARWR Sharpe Ratio Rank: 100
ARWR Sortino Ratio Rank: 99
ARWR Omega Ratio Rank: 98
ARWR Calmar Ratio Rank: 100
ARWR Martin Ratio Rank: 100

ELA

ELA Risk / Return Rank: 98
ELA Sharpe Ratio Rank: 99
ELA Sortino Ratio Rank: 98
ELA Omega Ratio Rank: 97
ELA Calmar Ratio Rank: 99
ELA Martin Ratio Rank: 99

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

ARWR vs. ELA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Arrowhead Pharmaceuticals, Inc. (ARWR) and Envela Corporation (ELA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	ARWR	ELA	Difference
Sharpe ratio: Return per unit of total volatility	6.69	4.23	+2.46
Sortino ratio: Return per unit of downside risk	5.72	4.35	+1.37
Omega ratio: Gain probability vs. loss probability	1.70	1.56	+0.15
Calmar ratio: Return relative to maximum drawdown	17.83	10.61	+7.22
Martin ratio: Return relative to average drawdown	51.66	31.31	+20.34

ARWR vs. ELA - Sharpe Ratio Comparison

The current ARWR Sharpe Ratio is 6.69, which is higher than the ELA Sharpe Ratio of 4.23. The chart below compares the historical Sharpe Ratios of ARWR and ELA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

ARWR vs. ELA - Drawdown Comparison

The maximum ARWR drawdown since its inception was -99.24%, roughly equal to the maximum ELA drawdown of -97.32%. Use the drawdown chart below to compare losses from any high point for ARWR and ELA.

Drawdown Indicators

	ARWR	ELA	Difference
Max Drawdown Largest peak-to-trough decline	-99.24%	-97.32%	-1.92%
Max Drawdown (1Y) Largest decline over 1 year	-24.64%	-28.50%	+3.86%
Max Drawdown (3Y) Largest decline over 3 years	-74.70%	-45.05%	-29.65%
Max Drawdown (5Y) Largest decline over 5 years	-87.89%	-61.53%	-26.36%
Max Drawdown (10Y) Largest decline over 10 years	-88.96%	-78.03%	-10.93%
Current Drawdown Current decline from peak	-47.91%	-24.93%	-22.98%
Average Drawdown Average peak-to-trough decline	-81.07%	-57.46%	-23.61%
Ulcer Index Depth and duration of drawdowns from previous peaks	8.49%	9.63%	-1.14%

Volatility

ARWR vs. ELA - Volatility Comparison

Arrowhead Pharmaceuticals, Inc. (ARWR) has a higher volatility of 23.10% compared to Envela Corporation (ELA) at 11.58%. This indicates that ARWR's price experiences larger fluctuations and is considered to be riskier than ELA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ARWR	ELA	Difference
Volatility (1M) Calculated over the trailing 1-month period	23.10%	11.58%	+11.52%
Volatility (6M) Calculated over the trailing 6-month period	39.03%	51.12%	-12.09%
Volatility (1Y) Calculated over the trailing 1-year period	65.63%	71.58%	-5.95%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	64.63%	54.09%	+10.54%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	74.38%	65.23%	+9.15%

Dividends

ARWR vs. ELA - Dividend Comparison

Neither ARWR nor ELA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both ARWR and ELA in my portfolio?

ARWR and ELA have a correlation of 0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ARWR or ELA?

ARWR has higher volatility (23.10%) compared to ELA (11.58%). In terms of maximum drawdown, ARWR dropped -99.24% vs ELA's -97.32%.

Which has better risk-adjusted returns?

ARWR currently has the higher Sharpe Ratio (6.69 vs 4.23), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.